Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

Journal of Clinical Investigation

Volumn 129, Issue 1, 2019, Pages

  Pai, Chien Chun Steven ^a   Simons, Donald M ^b   Lu, Xiaoqing ^b   Evans, Michael ^a   Wei, Junnian ^a   Wang, Yung Hua ^a   Chen, Mingyi ^c   Huang, John ^a   Park, Chanhyuk ^a   Chang, Anthony ^a   Wang, Jiaxi ^a   Westmoreland, Susan ^b   Beam, Christine ^b   Banach, Dave ^b   Bowley, Diana ^b   Dong, Feng ^b   Seagal, Jane ^b   Ritacco, Wendy ^b   Richardson, Paul L ^b   Mitra, Soumya ^b   Lynch, Grace ^b   Bousquet, Pete ^b   Mankovich, John ^b   Kingsbury, Gillian ^b,e   Fong, Lawrence ^a,d   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ABBVIE INC   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e AGIOS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DUAL VARIABLE DOMAIN IMMUNOGLOBULIN OF CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FC RECEPTOR; IPILIMUMAB; MATRIPTASE; RAG1 PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CTLA4 PROTEIN, MOUSE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; REGULATORY T LYMPHOCYTE; TRAMP-C2 CELL LINE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; WILD TYPE MOUSE; ANIMAL; CELLULAR IMMUNITY; DRUG EFFECT; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CELL LINE, TUMOR; CTLA-4 ANTIGEN; HEK293 CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MALE; MICE; MICE, KNOCKOUT; NEOPLASMS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 85059413620     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI123391     Document Type: Article

References (49)

1. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immun. 2013;13:5.
2. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(9):4275-4280.
3. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270-1271.
4. Brahmer JR, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768.
5. Wolchok JD, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-1356.
6. Walunas TL, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405-413.
7. Paterson AM, Sharpe AH. Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells. Nat Immunol. 2010;11(2):109-111.
8. Ise W, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol. 2010;11(2):129-135.
9. Takahashi T, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303-310.
10. Simpson TR, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695-1710.
11. Cha E, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014;6(238):238ra70.
12. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.
13. Ishihara J, et al. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017;9(415):eaan0401.
14. Fassò M, et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008;105(9):3509-3514.
15. Bok RA, Hansell EJ, Nguyen TP, Greenberg NM, McKerrow JH, Shuman MA. Patterns of protease production during prostate cancer progression: Proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis. 2003;6(4):272-280.
16. Truillet C, et al. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018;29(1):96-103.
17. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: A multidisciplinary approach. Oncologist. 2013;18(6):733-743.
18. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
19. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
20. Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57(8):2233-2240.
21. Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest. 2013;143(3):858-861.
22. Franzen D, et al. Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: A prospective observational study. Cancer Immunol Immunother. 2018;67(1):127-134.
23. Illouz F, et al. Endocrine toxicity of immune checkpoint inhibitors: Essential crosstalk between endocrinologists and oncologists. Cancer Med. 2017;6(8):1923-1929.
24. Sznol M, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70-76.
25. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717-1725.
26. Komatsu N, Hori S. Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc Natl Acad Sci U S A. 2007;104(21):8959-8964.
27. Ostanin DV, et al. T cell transfer model of chronic colitis: Concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G135-G146.
28. Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med. 1993;178(1):237-244.
29. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006;212:256-271.
30. Liakou CI, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008;105(39):14987-14992.
31. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541-547.
32. Michot JM, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer. 2016;54:139-148.
33. Tai X, et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood. 2012;119(22):5155-5163.
34. Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology. 2014;3(1):e27614.
35. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol. 2008;9(3):239-244.
36. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
37. Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A. 2016;113(17):E2383-E2392.
38. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A. 2001;98(5):2658-2663.
39. Beers SA, Glennie MJ, White AL. Influence of immunoglobulin isotype on therapeutic antibody function. Blood. 2016;127(9):1097-1101.
40. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28(3):285-295.
41. Romano E, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112(19):6140-6145.
42. Kavanagh B, et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008;112(4):1175-1183.
43. Sharma A, et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers [published online ahead of print July 27, 2018]. Clin Cancer Res. https://doi. org/10.1158/1078-0432.CCR-18-0762.
44. Selby MJ, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32-42.
45. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A. 2012;109(16):6181-6186.
46. Arce Vargas F, et al. Fc effector function contributes to the activity of human anti-ctla-4 antibodies. Cancer Cell. 2018;33(4):649-663.e4.
47. Gül N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by macrophages: A potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. 2015;75(23):5008-5013.
48. Wu C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007;25(11):1290-1297.
49. Gu J, Ghayur T. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Meth Enzymol. 2012;502:25-41.